Brief: XSpray Pharma: Dasynoc Granted Orphan Drug Designation In US
17/06/2022 08:13
June 17 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST :
* DASYNOC GRANTED ORPHAN DRUG DESIGNATION IN US FOR
TREATMENT OF
CHRONIC MYELOID LEUKEMIA
* FDA HAS GRANTED DASYNOC ORPHAN DRUG DESIGNATION (ODD) IN
US FOR
TREATMENT OF CHRONIC MYELOID LEUKEMIA
Source text for Eikon: ID:nMFN9nXBwX
Further company coverage: XSPRAY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003